Priche Generics Profile
Key Indicators
- Authorised Capital ₹ 8.50 Cr
as on 01-01-2025
- Paid Up Capital ₹ 1.65 Cr
as on 01-01-2025
- Company Age 8 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 49.47 Cr
as on 01-01-2025
- Revenue %
(FY 2019)
- Ebitda
- Net Worth
- Total Assets -0.25%
(FY 2019)
About Priche Generics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 8.50 Cr and a paid-up capital of Rs 1.65 Cr.
The company currently has active open charges totaling ₹49.47 Cr.
Subbarao Kattamuri and Sushma Kattamuri serve as directors at the Company.
- CIN/LLPIN
U74999TG2016PTC112294
- Company No.
112294
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Oct 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Priche Generics?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Subbarao Kattamuri  | Director | 04-Oct-2016 | Current |
| Sushma Kattamuri | Director | 10-Aug-2024 | Current |
Financial Performance of Priche Generics.
Priche Generics Private Limited, for the financial year ended 2019, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Priche Generics?
In 2019, Priche Generics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Evertogen Life Sciences LimitedActive 12 years 8 daysSubbarao Kattamuri and Sushma Kattamuri are mutual person
K.R.R. Drugs & Intermediates Private LimitedActive 22 years 11 monthsSubbarao Kattamuri is a mutual person
- Lytica Labs Private LimitedActive 7 years 1 month
Subbarao Kattamuri and Sushma Kattamuri are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 02 May 2022 | ₹37.47 Cr | Open |
Others Creation Date: 24 Jan 2001 | ₹12.00 Cr | Open |
How Many Employees Work at Priche Generics?
Unlock and access historical data on people associated with Priche Generics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Priche Generics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Priche Generics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
